median effective dose
Showing 1 - 25 of >10,000
Succinylcholine, Myofibrillation Trial in Yangzhou (rocuronium)
Enrolling by invitation
- Succinylcholine
- Myofibrillation
-
Yangzhou, Jiangsu, Chinathe Affiliated Hospital of Yangzhou University, Yangzhou Univers
Jun 10, 2023
Fasciculation, Succinylcholine Trial in Yangzhou (Cisatracurium)
Recruiting
- Fasciculation
- Succinylcholine
-
Yangzhou, Jiangsu, Chinathe Affiliated Hospital of Yangzhou University
Feb 26, 2023
Dose, Midazolam, Preoperative Trial in Guangzhou (Midazolam oral solution)
Not yet recruiting
- Dose
- +2 more
- Midazolam oral solution
-
Guangzhou, Guangdong, Chinathe Sixth Affiliated Hospital, Sun Yat-sen University
Aug 24, 2023
Autism Spectrum Disorder Trial (Esketamine, Propofol)
Not yet recruiting
- Autism Spectrum Disorder
- (no location specified)
Jul 17, 2023
Rocuronium, Injection Pain Trial in Yangzhou (Remifentanil)
Recruiting
- Rocuronium
- Injection Pain
-
Yangzhou, Jiangsu, Chinathe Affiliated Hospital of Yangzhou University
Jan 31, 2022
Diabetic Foot, Diabetic Neuropathies Trial in Seoul (Maintain the concentration of ropivacaine as same as those used in the
Recruiting
- Diabetic Foot
- Diabetic Neuropathies
- Maintain the concentration of ropivacaine as same as those used in the previous participant
- +2 more
-
Seoul, Korea, Republic ofSeoul National University Hospital
Feb 2, 2022
Lidocaine, Injection Pain Trial in Yangzhou (Lidocaine)
Completed
- Lidocaine
- Injection Pain
-
Yangzhou, Jiangsu, Chinathe Affiliated Hospital of Yangzhou University, Yangzhou Univers
Jan 30, 2020
Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)
Not yet recruiting
- Adverse Effect
- Alpha-Agonist
- α-adrenergic receptor agonist
- (no location specified)
Nov 28, 2023
Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)
Not yet recruiting
- Adverse Effect
- Alpha-Agonist
- α-adrenergic receptor agonist
- (no location specified)
Nov 28, 2023
Effect of Drug Trial (Remimazolam tosilate)
Not yet recruiting
- Effect of Drug
- Remimazolam tosilate
- (no location specified)
May 17, 2023
Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)
Not yet recruiting
- Adverse Effect
- Alpha-Agonist
- α-adrenergic receptor agonist
- (no location specified)
Nov 28, 2023
Adverse Effect Trial (Alpha-Agonist, a-adrenergic receptor agonist)
Not yet recruiting
- Adverse Effect
- Alpha-Agonist
- α-adrenergic receptor agonist
- (no location specified)
Nov 28, 2023
PD - Parkinson's Disease Trial in Beijing (Dexmedetomidine)
Recruiting
- PD - Parkinson's Disease
-
Beijing, Beijing, ChinaBeijing Tiantan hospital
Jun 16, 2022
Hemodynamics Trial in Shanghai (The median dose of esketamine, The high dose of esketamine, Propofol)
Recruiting
- Hemodynamics
- The median dose of esketamine
- +2 more
-
Shanghai, Shanghai, ChinaAnesthesiology Department of Affiliated Eye and ENT Hospital, Fu
Feb 21, 2023
Drug Effect Trial in Seoul (Remimazolam besylate)
Not yet recruiting
- Drug Effect
- Remimazolam besylate
-
Seoul, Korea, Republic ofSeoul National University Hospital
Aug 3, 2023
Anxiety Trial (Mozart selections, Patient-preferred music selections)
Not yet recruiting
- Anxiety
- Mozart selections
- Patient-preferred music selections
- (no location specified)
Jul 20, 2023
Remimazolam, Orthopedic Procedures, Sedatives Trial in Seoul (Remimazolam)
Completed
- Remimazolam
- +3 more
-
Seoul, Korea, Republic ofAsan Medical Center
Dec 15, 2022
Acute Asthma Trial in Detroit (arformoterol (RR formoterol), , levalbuterol)
Terminated
- Acute Asthma
- arformoterol (RR formoterol)
- +2 more
-
Detroit, MichiganHenry Ford Hospital Emergency Department
Jan 6, 2023
Lung Cancer, Anesthesia Induction Trial in Shanghai (Dexmedetomidine, Remimazolam tosilate)
Recruiting
- Lung Cancer
- Anesthesia Induction
- Dexmedetomidine
- Remimazolam tosilate
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Nov 29, 2022